A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study

Jacobson Ira M.; Asselah Tarik; Nahass Ronald; Bhandari Bal R.; Tran Albert; Hyland Robert H.; Stamm Luisa M.; Dvory-Sobol Hadas; Zhu Yanni; Brainard Diana M.; Subramanian Mani; McHutchison John G.; Shafran Stephen; Davis Mitchell; Stedman Catherine A.; Lawitz Eric; Gane Edward J.

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study

【24h】

A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study

机译：在DAA初次感染1-6型HCV的患者中，Sofosbuvir / Velpatasvir / Voxilaprevir进行了8周的随机3期试验，与Sofosbuvir / Velpatasvir进行了12周的随机试验比较：POLARIS-2研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2016年第6期|共1页
作者
Jacobson Ira M.; Asselah Tarik; Nahass Ronald; Bhandari Bal R.; Tran Albert; Hyland Robert H.; Stamm Luisa M.; Dvory-Sobol Hadas; Zhu Yanni; Brainard Diana M.; Subramanian Mani; McHutchison John G.; Shafran Stephen; Davis Mitchell; Stedman Catherine A.; Lawitz Eric; Gane Edward J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献

1. A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study [J] . Jacobson Ira M., Asselah Tarik, Nahass Ronald, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第6期

机译：在DAA初次感染1-6型HCV的患者中，Sofosbuvir / Velpatasvir / Voxilaprevir进行了8周的随机3期试验，与Sofosbuvir / Velpatasvir进行了12周的随机试验比较：POLARIS-2研究
2. A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks for Patients with Genotype 3 HCV Infection and Cirrhosis: The POLARIS-3 Study [J] . Foster Graham R., Thompson Alex J., Ruane Peter J., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Sofosbuvir / Velpatasvir / Voxilaprevir的随机相3试验8周和Sofosbuvir / Velpatasvir为基因型3 HCV感染和肝硬化的患者进行12周：Polaris-3研究
3. LBO‐06: Retreatment with Sofosbuvir/Velpatasvir/Voxilaprevir for 12?weeks is safe and effective for patients who have previously received Sofosbuvir/Velpatasvir or Sofosbuvir/Velpatasvir/Voxilaprevir [J] . Journal of viral hepatitis. . 2018,第S1期

机译：LBO-06：与Sofosbuvir / Velpatasvir / Voxilaprevir的恢复12？周是安全有效的，对于先前接受Sofosbuvir / Velpatasvir或Sofosbuvir / Velpatasvir / Voxilaprevir的患者
4. The early external cephalic version (ECV) trial: A randomised controlled trial of ECV beginning at between 34--36 weeks compared to 37--38 weeks gestation. [D] . Hutton, Eileen Katherine McNally. 2003

机译：早期体外头颅试验（ECV）：一项ECV随机对照试验始于妊娠34--36周，而妊娠37--38周。
5. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective Multicenter Study [O] . Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, 2020

机译：12周Sofosbuvir / VelpataSvir治疗对代错的肝硬化患者的实际世界临床应用1和2：一项潜在的多中心研究
6. Sofosbuvir/velpatasvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients [O] . Kosh Agarwal, Lluís Castells, Beat Müllhaupt, 2018

机译：Sofosbuvir / Velpatasvir在基因型中为12周1-4 HCV感染肝移植受者

A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study

著录项

相似文献

相关主题

期刊订阅